Glaucoma & Uveitis Risk: Prostaglandin Analogs Best
- patients using prostaglandin analogs for glaucoma treatment showed a reduced risk of developing uveitis compared to those using other topical medications, according to a study in Ophthalmology Glaucoma.
- Chauhan, of the Harvey and Bernice Jones eye Institute at the University of Arkansas for Medical Sciences, and colleagues noted the relationship between glaucoma medications and uveitis has...
- Researchers analyzed data from over 64,000 patients from 10 health systems, comparing new uveitis diagnoses within three months of starting glaucoma medication.The study included alpha agonists (16.7%), beta-blockers...
Prostaglandin analogs (primarykeyword) offer a meaningful advantage for glaucoma patients, according to new research. A study published in Ophthalmology Glaucoma reveals that individuals using these medications experienced a notably reduced risk of developing uveitis. This is contrary to previous concerns. The analysis of over 64,000 patients across ten health systems found that those using prostaglandin analogs had a uveitis rate of only 0.32%, substantially lower than with other glaucoma treatments like alpha agonists. The research also showed those with chronic uveitis fared best taking prostaglandin analogs.This data could reshape glaucoma treatment, particularly for those with pre-existing inflammation—a crucial point for patient care. News Directory 3 provides timely health updates. Could these findings influence future treatment protocols? Discover what’s next in glaucoma management. (secondarykeyword)
Prostaglandin Analogs Linked to Lower Uveitis Risk in Glaucoma Patients
Updated May 30, 2025
patients using prostaglandin analogs for glaucoma treatment showed a reduced risk of developing uveitis compared to those using other topical medications, according to a study in Ophthalmology Glaucoma.
Dr. Muhammad Z. Chauhan, of the Harvey and Bernice Jones eye Institute at the University of Arkansas for Medical Sciences, and colleagues noted the relationship between glaucoma medications and uveitis has been debated. They added that large studies on uveitis incidence across different glaucoma medication classes remain scarce.
Data derived from Chauhan MZ, et al. Ophthalmol Glaucoma. 2025; two: 10.1016/J.Oogla.2024.10.010.
Researchers analyzed data from over 64,000 patients from 10 health systems, comparing new uveitis diagnoses within three months of starting glaucoma medication.The study included alpha agonists (16.7%), beta-blockers (17.5%), prostaglandin analogs (62%) and carbonic anhydrase inhibitors (3.7%).
Of the participants, 567 developed uveitis within three months of starting medication. prostaglandin analogs had the lowest uveitis rate (0.32%), followed by alpha agonists (1.63%), carbonic anhydrase inhibitors (1.68%) and beta-blockers (1.95%).
The risk of uveitis was approximately five to six times higher with beta-blockers, carbonic anhydrase inhibitors, and alpha agonists compared to prostaglandin analogs (P < .001 for all). Thes comparisons accounted for sociodemographic factors.
patients with a history of chronic uveitis initiating prostaglandin analogs experienced the lowest rate of acute flares within three months (0.35%),compared to those on carbonic anhydrase inhibitors (1.92%), alpha agonists (1.97%) and beta-blockers (2.4%).
Chauhan and colleagues stated their findings challenge the idea of prostaglandin analogs as a risk factor for uveitis exacerbation in glaucoma patients. They suggest a reevaluation of glaucoma treatment, especially for those with pre-existing inflammation.
The researchers added that prostaglandin analogs, which favor the uveoscleral outflow pathway, may be well-suited for lowering intraocular pressure in uveitis patients due to the compromised trabecular pathway.
Patients prescribed PGAs did not exhibit an increased risk of developing subsequent uveitis compared with those treated with other classes of glaucoma medications. This finding calls into question the perception that PGAs are proinflammatory.
Joe L. Wheat, Associate professor, University of Houston College of Optometry
What’s next
Further research is needed to explore the varied etiology and severity that encompass uveitis as a whole, even as this study raises significant questions regarding prostaglandin analog use in patients with a history of uveitis.